Detecting even more viruses – in 9 hours rather than 5 weeks
New ViroInspect Rodent 2 test kit module identifies 11 adventitious viruses. Webinar with presentation for professional audience.
Frickenhausen, 24th May 2016 – Greiner Bio-One, a technology partner for the diagnostic and pharmaceutical industry, will be using June′s international Viral Safety Conference in Cologne to present the second module of the ViroInspect test system it unveiled last year. The new ViroInspect Rodent 2 kit detects 11 adventitious viruses that can cause contamination during the production of biopharmaceuticals.
Second module identifies further viruses
Viruses that use rodents as natural hosts and often infect CHO cells can occur in biopharmaceutical production sites as contaminations during biofermentation. This endangers patients′ health. ViroInspect Rodent 2 is the second module in the Inspect product line and helps users meet all regulatory requirements related to product safety. ViroInspect Rodent 1 already identifies rodent parvoviruses, porcine circoviruses 1 and 2, and Vesivirus 2117. Rodent 2 now also enables rapid detection of certain noroviruses, rotaviruses, pneumoviruses and cardioviruses as well as betacoronaviruses, rubulaviruses, respiroviruses and orthoreoviruses.
Quick decision in just a few hours
ViroInspect Rodent 2′s innovative nucleic acid amplification testing (NAAT) provides a broad target panel for highly sensitive detection out of large sample volumes. The complete kit package comprises all steps from sample preparation up to result determination. High specificity is ensured by three selective levels (PCR, hybridisation and detection). Automatic evaluations and reports deliver clear-cut results that are easy to document. Virus detection and identification starts with extraction of genetic material and is completed within just nine hours – as opposed to conventional in vivo and in vitro tests, which require up to five weeks.
The microarray-based test kit includes sample preparation, extraction of genetic material, reverse transcription, microarray hybridisation and software-based evaluation, and is validated in compliance with ICH guideline Q2(R1).
Greiner Bio-One will be joining forces with British scientific publisher and conference organiser INFORMA PLC to present the product innovation to professional audience in a webinar at 3 p.m. CET, on 1 June 2016.
Participation is free, but prior registration is necessary and is possible via this link:
Greiner Bio-One International GmbH
Greiner Bio-One specialises in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into four divisions – Preanalytics, BioScience, Diagnostics and OEM. In 2015, Greiner Bio-One International GmbH generated a turnover of 427 million euros and had over 1,890 employees, 23 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).
Greiner Bio-One Diagnostics division
The Greiner Bio-One Diagnostics division produces and markets test products for human diagnostics, biopharmaceutical production and the food sector.
Ensuring vaccine safety and identifying sexually transmitted diseases are among the applications of the various test methods. PapilloCheck®, CytoInspect™, ViroInspect® and CarnoCheck® are the products on which Greiner Bio-One Diagnostics will be focusing in the future.
For further information please contact:
Greiner Bio-One GmbH
Phone: +49 (0) 7022 / 948-0
Fax: +49 (0) 7022 / 948-514
Zeeb Kommunikation GmbH
Hohenheimer Strasse 58a
Phone: +49 (0) 711 / 60707-19
Fax: +49 (0) 711 / 60707-39